Combination Treatment of OSI-906 with Aurora B Inhibitor Reduces Cell Viability via Cyclin B1 Degradation-Induced Mitotic Slippage

Int J Mol Sci. 2021 May 27;22(11):5706. doi: 10.3390/ijms22115706.

Abstract

Insulin-like growth factor 1 receptor (IGF1R), a receptor-type tyrosine kinase, transduces signals related to cell proliferation, survival, and differentiation. We recently reported that OSI-906, an IGF1R inhibitor, in combination with the Aurora B inhibitor ZM447439 suppresses cell proliferation. However, the mechanism underlying this suppressive effect is yet to be elucidated. In this study, we examined the effects of combination treatment with OSI-906 and ZM447439 on cell division, so as to understand how cell proliferation was suppressed. Morphological analysis showed that the combination treatment generated enlarged cells with aberrant nuclei, whereas neither OSI-906 nor ZM447439 treatment alone caused this morphological change. Flow cytometry analysis indicated that over-replicated cells were generated by the combination treatment, but not by the lone treatment with either inhibitors. Time-lapse imaging showed mitotic slippage following a severe delay in chromosome alignment and cytokinesis failure with furrow regression. Furthermore, in S-trityl-l-cysteine-treated cells, cyclin B1 was precociously degraded. These results suggest that the combination treatment caused severe defect in the chromosome alignment and spindle assembly checkpoint, which resulted in the generation of over-replicated cells. The generation of over-replicated cells with massive aneuploidy may be the cause of reduction of cell viability and cell death. This study provides new possibilities of cancer chemotherapy.

Keywords: Aurora B; IGF1R; M phase; OSI-906; RO-3306; ZM447439; linsitinib.

MeSH terms

  • Aurora Kinase B / antagonists & inhibitors*
  • Benzamides / pharmacology
  • Cell Cycle / drug effects
  • Cell Line, Tumor
  • Cell Proliferation / drug effects
  • Cell Survival / drug effects*
  • Cyclin B1 / metabolism*
  • Dose-Response Relationship, Drug
  • Humans
  • Imidazoles / pharmacology*
  • Lung Neoplasms / drug therapy
  • Lung Neoplasms / genetics
  • Lung Neoplasms / metabolism
  • Lung Neoplasms / pathology
  • Mitosis / drug effects*
  • Protein Kinase Inhibitors / pharmacology*
  • Proteolysis
  • Pyrazines / pharmacology*
  • Quinazolines / pharmacology
  • Receptor, IGF Type 1 / metabolism

Substances

  • 3-(8-amino-1-(2-phenylquinolin-7-yl)imidazo(1,5-a)pyrazin-3-yl)-1-methylcyclobutanol
  • 4-(4-(N-benzoylamino)anilino)-6-methoxy-7-(3-(1-morpholino)propoxy)quinazoline
  • Benzamides
  • Cyclin B1
  • IGF1R protein, human
  • Imidazoles
  • Protein Kinase Inhibitors
  • Pyrazines
  • Quinazolines
  • Receptor, IGF Type 1
  • AURKB protein, human
  • Aurora Kinase B